Log in
Enquire now
‌

US Patent 7476734 Nucleotide analogs

Patent 7476734 was granted and assigned to Helicos Biosciences on January, 2009 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
Helicos Biosciences
Helicos Biosciences
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
7476734
Date of Patent
January 13, 2009
Patent Application Number
11295155
Date Filed
December 6, 2005
Patent Citations Received
‌
US Patent 12084663 Incorporation of unnatural amino acids into proteins using base editing
0
‌
US Patent 11999947 Adenosine nucleobase editors and uses thereof
0
‌
US Patent 12006520 Evaluation and improvement of nuclease cleavage specificity
0
0
‌
US Patent 11661590 Programmable CAS9-recombinase fusion proteins and uses thereof
0
‌
US Patent 11912985 Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
0
‌
US Patent 11920181 Nuclease profiling system
0
‌
US Patent 11932884 High efficiency base editors comprising Gam
0
Patent Primary Examiner
‌
Patrick T. Lewis
Patent abstract

The invention provides nucleotide analogs for use in sequencing nucleic acid molecules.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7476734 Nucleotide analogs

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.